GlaxoSmithKline

News

Novartis antibiotic retreat doesn’t stop Sandoz buying GSK d...

Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalospor

News

ViiV’s Rukobia cleared in EU as rescue HIV therapy

The European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment for people with HIV that has developed resistance to other antiretroviral therapy (ART

News

GSK/CureVac target new COVID variants with next-gen shot

GlaxoSmithKline and CureVac are to begin developing a next generation vaccine targeting emerging variants of the coronavirus – although it is unlikely to be ready until at least next year.<

News

CHMP clears way for EU approval of Novartis' MS drug

Novartis’ multiple sclerosis drug has been given the green light by the European Medicines Agency’s CHMP scientific committee, paving the way for a likely approval in the coming weeks.

News

GSK suffers another R&D setback, axing ulcerative colitis dr...

GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with ulcerative colitis, following a major disappointment with a key lun

News

GSK/Merck's hopeful bintrafusp alfa fails in key lung cancer...

GlaxoSmithKline’s big gamble on a cancer drug developed by Germany’s Merck KGaA looks unlikely to pay out, after bintrafusp alfa failed to outperform US-based Merck & Co’s Keytruda in a

Novartis antibiotic retreat doesn’t stop Sandoz buying GSK d...

ViiV’s Rukobia cleared in EU as rescue HIV therapy

GSK/CureVac target new COVID variants with next-gen shot

CHMP clears way for EU approval of Novartis' MS drug

GSK suffers another R&D setback, axing ulcerative colitis dr...

GSK/Merck's hopeful bintrafusp alfa fails in key lung cancer...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

GlaxoSmithKline

Editor's Picks